Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, prospective, single arm phase 2 trial of the combination
of bendamustine and rituximab in patients with PTLD, monomorphic cluster of differentiation
antigen 20(CD20) positive DLBCL. The investigators want to investigate the efficacy and
safety of the combination of bendamustine and rituximab in patients with previously untreated
PTLD, monomorphic CD20 (+) diffuse large B-cell lymphoma.